Skip to main content Skip to section navigation Skip to footer

XORTX Therapeutics Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Advisory Board
  • Pipeline
    • Overview
    • XRx-008 for Autosomal Dominant Polycystic Kidney Disease
    • XRx-101 for Coronavirus/COVID-19
    • XRX-225 for Type 2 Diabetic Nephropathy
    • Publications
  • Technology
  • News & Media
    • Press Releases
    • Events
    • In the News
  • Investors
    • Overview
    • News & Events
    • Presentations
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • SEDAR
    • Governance
  • Contact

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Annual & Special Meeting of Shareholders
    • Email Alerts
  • Presentations
  • Company Info
    • Overview
    • Management Team
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
  • Stock Data
    • Analyst Coverage
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • SEDAR
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
    • Board Diversity Matrix
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Annual & Special Meeting of Shareholders
  • Email Alerts
Apr 29, 2019 5:09pm EDT

XORTX Provides Overview and Announces $5 Million Financing to Advance Clinical Trials

Apr 16, 2019 10:55am EDT

XORTX Shares Findings of Diabetes Study in Youths Supporting High Uric Acid Advances Kidney Disease Progression

Mar 25, 2019 7:00am EDT

XORTX Shares Findings of New Diabetes Study Supporting Uric Acid as an Independent Risk Factor

Mar 12, 2019 10:51am EDT

XORTX Signs LOI for Co-Development and Licensing Agreement with Japan’s Teijin Pharma Limited

Jan 28, 2019 7:00am EST

XORTX to Present at NobleConXV Noble Capital Markets’ 15th Annual Investor Conference

Nov 26, 2018 5:00pm EST

XORTX Receives FDA Response on Orphan Drug Designation Application

Nov 06, 2018 9:58pm EST

XORTX Announces Appointment of CFO

Oct 23, 2018 7:00am EDT

XORTX Announces Revision to Polycystic Kidney Disease Clinical Development Plan

Oct 15, 2018 7:00am EDT

XORTX Announces New Clinical Advisory Board Members

Sep 10, 2018 7:00am EDT

XORTX Announces Submission of Orphan Drug Designation Application

  • arrow_back
  • 1…
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • arrow_forward
rss_feed News RSS
  • Email Alerts
  • Contacts
  • RSS News Feed
©2023 XORTX Therapeutics Inc. All Rights Reserved.
Privacy Policy Disclaimer Sitemap